These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711 [TBL] [Abstract][Full Text] [Related]
26. Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010. Mohaghegh Shalmani H; Noori A; Shokoohi M; Khajavi A; Darvishi M; Delavari A; Jamshidi HR; Naderimagham S Arch Iran Med; 2015 Aug; 18(8):508-14. PubMed ID: 26265519 [TBL] [Abstract][Full Text] [Related]
27. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients. Nakagawa H; Fujiwara N; Tateishi R; Arano T; Nakagomi R; Kondo M; Minami T; Sato M; Uchino K; Enooku K; Asaoka Y; Kondo Y; Shiina S; Yoshida H; Koike K J Gastroenterol Hepatol; 2015 Feb; 30(2):379-88. PubMed ID: 25168107 [TBL] [Abstract][Full Text] [Related]
28. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648 [TBL] [Abstract][Full Text] [Related]
29. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368 [TBL] [Abstract][Full Text] [Related]
30. Disease burden of chronic hepatitis C among immigrants in Canada. Chen W; Krahn M J Viral Hepat; 2015 Dec; 22(12):1043-54. PubMed ID: 26110922 [TBL] [Abstract][Full Text] [Related]
31. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537 [TBL] [Abstract][Full Text] [Related]
32. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. Innes H; Goldberg D; Dusheiko G; Hayes P; Mills PR; Dillon JF; Aspinall E; Barclay ST; Hutchinson SJ J Hepatol; 2014 Jun; 60(6):1118-26. PubMed ID: 24509410 [TBL] [Abstract][Full Text] [Related]
34. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS; Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403 [TBL] [Abstract][Full Text] [Related]
35. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Mohanty A; Erqou S; McGinnis KA; Vanasse G; Freiberg MS; Sherman KE; Butt AA Clin Gastroenterol Hepatol; 2013 Jun; 11(6):741-7.e3. PubMed ID: 23376794 [TBL] [Abstract][Full Text] [Related]
36. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). Klein MB; Rollet-Kurhajec KC; Moodie EE; Yaphe S; Tyndall M; Walmsley S; Gill J; Martel-Laferriere V; Cooper C; AIDS; 2014 Aug; 28(13):1957-65. PubMed ID: 25259703 [TBL] [Abstract][Full Text] [Related]
37. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013. Johnson NB; Hayes LD; Brown K; Hoo EC; Ethier KA; MMWR Suppl; 2014 Oct; 63(4):3-27. PubMed ID: 25356673 [TBL] [Abstract][Full Text] [Related]
38. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Bedogni G; Miglioli L; Masutti F; Ferri S; Castiglione A; Lenzi M; Crocè LS; Granito A; Tiribelli C; Bellentani S Am J Gastroenterol; 2008 Sep; 103(9):2248-53. PubMed ID: 18637095 [TBL] [Abstract][Full Text] [Related]
39. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707 [TBL] [Abstract][Full Text] [Related]
40. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Moucari R; Asselah T; Cazals-Hatem D; Voitot H; Boyer N; Ripault MP; Sobesky R; Martinot-Peignoux M; Maylin S; Nicolas-Chanoine MH; Paradis V; Vidaud M; Valla D; Bedossa P; Marcellin P Gastroenterology; 2008 Feb; 134(2):416-23. PubMed ID: 18164296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]